rs891512 — NOS3

NOS3 IVS25+15 — The Blood Pressure Variant Wired to Exercise

Your NOS3 gene encodes endothelial nitric oxide synthase (eNOS), the enzyme that produces nitric oxide (NO)¹¹ nitric oxide (NO)
a gaseous signaling molecule that dilates blood vessels, prevents platelet aggregation, and protects the endothelium from inflammation and atherosclerosis. Without adequate NO, blood vessels stay more constricted and arterial stiffness rises in the cells lining your blood vessels. Among the many variants studied in this gene, rs891512 stands out for a specific reason: in a study genotyping 11 NOS3 polymorphisms across 726 participants from the MRC Ely Study, it was the only variant significantly associated with blood pressure²² only variant significantly associated with blood pressure
Vimaleswaran KS et al. Habitual energy expenditure modifies the association between NOS3 gene polymorphisms and blood pressure. Am J Hypertension, 2008 at rest. The association was strongest in physically active individuals, making rs891512 a clinically relevant gene-lifestyle interaction variant.

The Mechanism

rs891512 is located within intron 25 of NOS3 (IVS25+15 G>A) — 15 nucleotides into the intron after exon 25. On the GRCh38 reference genome the G allele is most common (~80% globally), while the A allele appears at roughly 20% in Europeans. Although intronic variants do not change the amino acid sequence, they can alter splicing factor binding³³ splicing factor binding
Splicing factors are proteins that direct how pre-mRNA introns are removed and exons joined together. Binding sites for these factors are concentrated near intron-exon junctions, and a variant that alters a binding site can cause aberrant splicing — including exon skipping or inclusion of intronic sequence — that disrupts the final protein. Bioinformatic analysis of rs891512 predicts that the A allele alters binding of the SF2/ASF splicing factor⁴⁴ SF2/ASF splicing factor
Serine/arginine-rich splicing factor 1 (SRSF1), a key regulator of constitutive and alternative splicing that binds exonic and intronic splicing enhancers, potentially causing defective splicing that yields a truncated or altered eNOS protein with lower enzymatic activity.

This mechanism aligns with what is known about NOS3 alternative splicing: truncated eNOS isoforms can form heterodimers with full-length enzyme and reduce overall NO output⁵⁵ NO output
Lorenz M et al. Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity. FASEB J, 2007. The functional consequence is lower vascular NO bioavailability — the same downstream effect as the well-characterized Glu298Asp (rs1799983) coding variant, but through a different molecular route.

The Evidence

The most rigorous study of rs891512 comes from the MRC Ely Study of 726 adults⁶⁶ MRC Ely Study of 726 adults
Vimaleswaran KS et al. Habitual energy expenditure modifies the association between NOS3 gene polymorphisms and blood pressure. Am J Hypertension, 2008. Researchers genotyped 11 NOS3 polymorphisms and found that among all variants tested, only IVS25+15 (rs891512) was independently associated with resting blood pressure. GG homozygotes had diastolic BP 2.8 mmHg lower (P = 0.016) and systolic BP 1.9 mmHg lower (P = 0.018) than A-allele carriers. Crucially, this effect was amplified by physical activity: in the most active tertile, GG homozygotes showed BP reductions of 4.9 mmHg diastolic and 3.8 mmHg systolic compared to A-allele carriers — a compelling gene-lifestyle interaction.

Cardiovascular disease associations have been reported in a Tunisian cohort of 274 CAD cases and 162 controls⁷⁷ a Tunisian cohort of 274 CAD cases and 162 controls
Letaief Afef et al. Endothelial nitric oxide gene polymorphisms and their association with coronary artery disease in Tunisian population. Anatol J Cardiol, 2017. The A allele was significantly enriched in cases (28.8%) versus controls (16.9%), with an OR for CAD of 1.99 (95% CI 1.40–2.82; P < 0.001). The genotype distribution difference between cases (AA 11.4%, GA 34.7%, GG 53.9%) and controls (AA 2.5%, GA 29.7%, GG 67.8%) was also statistically significant (P = 0.006). A smaller Chilean study in type 2 diabetes patients⁸⁸ smaller Chilean study in type 2 diabetes patients
Seelenfreund D et al. Association of the intronic polymorphism rs891512 (G24943A) of the endothelial nitric oxide synthase gene with hypertension in Chilean type 2 diabetes patients. Diabetes Res Clin Pract, 2012 (n = 93 patients, 76 controls) found significant association of the A allele with hypertension (p < 0.05), with A-allele frequency of 15% in that population.

In exercise genetics, deep-targeted NOS3 sequencing found that after vigorous-intensity cycling (100% VO2 peak), the A allele explained 5.6–7.6% of the variance in post-exercise hypotension among African American participants (P < 0.001 for diastolic BP), with minor allele carriers showing a substantially larger post-exercise BP decrease than GG homozygotes. The effect was absent at moderate intensity (60% VO2 peak), indicating the interaction is exercise-intensity-specific.

Practical Implications

The core finding for A-allele carriers is that your resting blood pressure tends to run modestly higher than the GG genotype. The good news embedded in the data is that the genetic disadvantage shrinks substantially with physical activity — GG carriers who are active show the largest benefit, but the data also imply that A-allele carriers who are habitually active narrow the BP gap considerably. Vigorous aerobic exercise appears to be particularly important, as the gene-exercise interaction is strongest at high exercise intensity.

Dietary nitrate from beetroot and nitrate-rich vegetables offers an alternative NO production pathway that is independent of eNOS altogether — it proceeds via the entero-salivary nitrate-nitrite-NO pathway. For A-allele carriers with elevated BP or blunted eNOS function, regular consumption of high-nitrate vegetables or beetroot juice (400–500 mg nitrate) can measurably reduce blood pressure and improve endothelial function.

Interactions

rs891512 is located in the same gene as the well-characterized Glu298Asp variant (rs1799983)⁹⁹ Glu298Asp variant (rs1799983)
missense variant changing amino acid 298 from glutamic acid to aspartic acid, making eNOS more susceptible to proteolytic degradation and reducing NO output, which affects eNOS protein stability. The two variants are in incomplete linkage disequilibrium, meaning they provide partially additive information about NOS3 function. Carrying risk alleles at both positions could compound reduced NO production through distinct mechanisms — impaired splicing (rs891512) and accelerated protein degradation (rs1799983).

The rs891512 exercise-BP interaction also suggests synergy with the promoter variant rs2070744 (T-786C)¹⁰¹⁰ rs2070744 (T-786C)
a regulatory variant that reduces NOS3 gene expression by approximately 25%; the T allele is protective and the C allele reduces promoter activity and eNOS mRNA levels, which affects eNOS transcription level. Compound actions for NOS3 multi-variant combinations should be considered when a user carries risk alleles at rs891512 and rs1799983 or rs2070744 simultaneously.